ANI Grabs 23 US Products From Amerigen

Deal Boosts Both Portfolio And Pipeline

In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.

Shopping_Trolley_Pills
ANI Pharmaceuticals has bought rights to 23 US generics from Amerigen • Source: Shutterstock

ANI Pharmaceuticals is paying Amerigen Pharmaceuticals up to $77.5m for a US portfolio of 23 approved and pipeline generics. The acquired portfolio includes 10 marketed products, three approved products for which launches are pending, four filed drugs, and four candidates that are currently under development, as well as a license to commercialize another two approved products. No further details were disclosed, but Amerigen’s focus is predominantly on oral-dose tablets and capsules.

Having funded the acquisition from cash at hand, ANI paid $52.5m on closing. Up to another $25m of payments over the next four years are contingent on annual gross profits from a subset of the acquired products exceeding a minimum threshold

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By 

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By 

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By 

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

More from Business